$9.60
Manufacturer: Ukraine
Benign peptic ulcer of the stomach and duodenum, including those associated with the use of non-steroidal anti-inflammatory drugs; gastroesophageal reflux disease; Zollinger-Ellison syndrome; for eradication of Helicobacter pylori (in combination with antibiotics).
Description
Lancerol Composition
active substance: lansoprazole;
1 capsule contains lansoprazole, in the composition of pellets, in terms of 100% substance 30 mg;
auxiliary substances (in the composition of pellets): sugar spheres (sucrose, corn starch, purified water) (0.85-1 mm), sodium lauryl sulfate, meglumine, mannitol (E 421), hypromellose (hydroxypropyl methylcellulose), macrogol 6000, talc, polysorbate 80, titanium dioxide (E 171), methacrylate copolymer (type A);
capsule shell composition: gelatin.
Lancerol Dosage form
Capsules.
Basic physical and chemical properties: hard gelatin capsules No. 1, body and lid are colorless, transparent. The contents of the capsules are white or almost white pellets.
Pharmacotherapeutic group. Drugs for the treatment of peptic ulcers and gastroesophageal reflux disease. Proton pump inhibitors.
ATX code A02B C03.
Lancerol Pharmacological properties
Pharmacodynamics
Lansoprazole inhibits the activity of the H + / K + -ATPase of the proton pump in the parietal cells of the gastric mucosa. Thus, Lancerol® inhibits the final stage of gastric acid formation, reduces the amount and acidity of gastric juice, as a result of which the harmful effect of gastric juice on the mucous membrane is reduced.
The degree of suppression is determined by the dose and duration of treatment. Even a single dose of 30 mg of lansoprazole inhibits gastric acid secretion by 70–90%. The onset of action is observed within 1-2 hours and continues throughout the day.
Pharmacokinetics
Lansoprazole is absorbed in the intestine. In healthy volunteers, when taking 30 mg of lansoprazole, the maximum plasma concentration is 0.75–1.15 mg / l and is reached within 1.5–2 hours. The maximum concentration in blood plasma and bioavailability depend on the individual characteristics of the patient and do not change depending on the frequency of taking the drug.
The binding of the drug to blood plasma proteins is 98%.
Lansoprazole is excreted from the body with bile and urine (only in the form of metabolites – lansoprazole sulfone and hydroxylanesoprazole), while 21% of the drug dose is excreted in the urine per day. The half-life is 1.5 hours.
The half-life is lengthened in patients with severe liver dysfunction and in patients over 69 years of age. In patients with impaired renal function, the absorption of lansoprazole is practically unchanged.
Lancerol Clinical characteristics.
Indications
Benign peptic ulcer of the stomach and duodenum, including those associated with the use of non-steroidal anti-inflammatory drugs;
gastroesophageal reflux disease;
Zollinger-Ellison syndrome;
for the eradication of Helicobacter pylori (in combination with antibiotics).
Contraindications
Hypersensitivity to lansoprazole or to any other component of the drug;
simultaneous use with atazanavir;
malignant neoplasms of the digestive tract.
Recent Reviews